Fig. 3: Association between pharmacological interventions and cardiovascular outcomes.

CI confidence interval; T total No. of studies; R randomized controlled trial; C cohort studies; GLP-1 RAs receptor agonists for glucagon-like peptide-1; MACE major adverse cardiac events; CVD cardiovascular disease; T2DM type 2 diabetes mellitus; NA not available, NS non-significant.